As mentioned above, PD-L1 glycosylation inhibits its ubiquitination-mediated degradation, prolongs the half-life of PD-L1, maintains PD-L1 stability, and promotes its binding to PD-1 to help tumor immune escape. Here, RPL17 is linked to neoplasm.